share_log

CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Stock Price Dropped 14% Last Week; Public Companies Would Not Be Happy

CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Stock Price Dropped 14% Last Week; Public Companies Would Not Be Happy

上週,長春高新生物經營的CK Life Sciences Int'l., (Holdings) Inc.(HKG:775)的股價下跌了14%; 這對上市公司來說並不是好消息
Simply Wall St ·  06/03 18:29

Key Insights

主要見解

  • Significant control over CK Life Sciences Int'l. (Holdings) by public companies implies that the general public has more power to influence management and governance-related decisions
  • A total of 2 investors have a majority stake in the company with 67% ownership
  • Insider ownership in CK Life Sciences Int'l. (Holdings) is 22%
  • 公衆公司對CK Life Sciences Int'l. (Holdings)的顯著控制意味着普通公衆有更大的權力來影響管理和治理相關決策。
  • 共有2名投資者擁有該公司的67%所有權。
  • CK Life Sciences Int'l. (Holdings)的內部所有權比例爲22%。

Every investor in CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) should be aware of the most powerful shareholder groups. With 45% stake, public companies possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).

CK Life Sciences Int'l. (Holdings) Inc. (HKG:775)的每一位投資者都應該意識到最強大的股東群體。公衆公司擁有45%的股份,是該公司的最大股東。換句話說,該群體面臨着最大的上行潛力(或下行風險)。

As a result, public companies as a group endured the highest losses last week after market cap fell by HK$529m.

因此,在市值下降了5.29億港元后,公衆公司作爲一個群體承受了最高的損失。

Let's take a closer look to see what the different types of shareholders can tell us about CK Life Sciences Int'l. (Holdings).

讓我們更仔細地觀察一下不同類型的股東對CK Life Sciences Int'l. (Holdings)有何啓示。

ownership-breakdown
SEHK:775 Ownership Breakdown June 3rd 2024
SEHK:775分時段所有權佔比2024年6月3日

What Does The Institutional Ownership Tell Us About CK Life Sciences Int'l. (Holdings)?

機構所有權告訴我們CK Life Sciences Int'l. (Holdings)的什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。

Less than 5% of CK Life Sciences Int'l. (Holdings) is held by institutional investors. This suggests that some funds have the company in their sights, but many have not yet bought shares in it. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. It is not uncommon to see a big share price rise if multiple institutional investors are trying to buy into a stock at the same time. So check out the historic earnings trajectory, below, but keep in mind it's the future that counts most.

不到5%的CK Life Sciences Int'l. (Holdings)由機構投資者持有。這表明一些資金將該公司視爲目標,但許多人尚未買入其股份。如果該業務從這裏變得更強,我們可能會看到更多的機構有意購買。如果多個機構投資者試圖同時買入股票,則看到價格出現大幅上漲並不罕見。因此,查看下面的歷史收益軌跡,但要記住,最重要的是未來。

earnings-and-revenue-growth
SEHK:775 Earnings and Revenue Growth June 3rd 2024
SEHK:775收益和營業收入增長2024年6月3日

We note that hedge funds don't have a meaningful investment in CK Life Sciences Int'l. (Holdings). The company's largest shareholder is CK Hutchison Holdings Limited, with ownership of 45%. For context, the second largest shareholder holds about 22% of the shares outstanding, followed by an ownership of 7.5% by the third-largest shareholder.

我們注意到,對CK Life Sciences Int'l. (Holdings)沒有實質性投資的對沖基金。該公司最大股東是長江和記實業有限公司,持股比例爲45%。爲了獲得背景信息,第二大股東持有約22%的流通股,第三大股東持有7.5%的股份。

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

爲了使我們的研究更有趣,我們發現前2名股東擁有該公司的大部分所有權,這意味着他們足夠強大,可以影響公司的決策。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.

研究公司的機構所有權可以爲您的研究增加價值,但同時調查分析師建議也是很好的做法,以更深入地了解股票的預期表現。我們目前沒有發現任何關於該公司的分析師報道,因此該公司不太可能被廣泛持有。

Insider Ownership Of CK Life Sciences Int'l. (Holdings)

CK Life Sciences Int'l. (Holdings)的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間有所不同。我們的數據反映了個人內部人員,至少捕捉到董事會成員的記錄。公司管理人員向董事會報告,後者應該代表股東的利益。值得注意的是,有時高級管理人員自己也在董事會中。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。

Our most recent data indicates that insiders own a reasonable proportion of CK Life Sciences Int'l., (Holdings) Inc.. Insiders have a HK$747m stake in this HK$3.4b business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

我們最新的數據表明,內部人員擁有CK Life Sciences Int'l. (Holdings) Inc.的相當比例。內部人員在這家市值爲34億港幣的公司中持有7.47億港幣的股份。這也許表明創始人仍擁有大量股份。你可以點擊這裏查看他們是否一直在買賣。

General Public Ownership

一般大衆所有權

The general public-- including retail investors -- own 24% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

包括散戶投資者在內的普通公衆擁有該公司24%的股份,因此不容忽視。雖然這個群體不能必然掌控局面,但它肯定會對公司經營方式產生真正的影響。

Private Company Ownership

私有公司的所有權

We can see that Private Companies own 7.5%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我們可以看到,非公開公司擁有該公司已發行股份的7.5%。僅從這個事實很難得出任何結論,因此值得研究誰擁有這些非公開公司。有時內部人員或其他相關方會通過單獨的私人公司持有公開公司的股份。

Public Company Ownership

上市公司所有權

We can see that public companies hold 45% of the CK Life Sciences Int'l. (Holdings) shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

我們可以看到,公衆公司持有CK Life Sciences Int'l. (Holdings)已發行股份的45%。這可能是戰略利益,兩家公司可能存在相關的業務利益。這意味着它們可能已經進行了拆分。這個持股是值得進一步調查的。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for CK Life Sciences Int'l. (Holdings) (of which 2 are significant!) you should know about.

雖然考慮擁有公司的不同群體很有價值,但其它更重要的因素也很重要。例如風險。每個公司都有它們自己的風險,我們已經發現CK Life Sciences Int'l. (Holdings)的4個風險預示(其中2個很重要!)你需要知道。

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

當然,這也可能不是最好的股票交易。因此,您可能想看看我們免費的潛力股票收藏,這些股票具有有利的財務狀況。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論